Arkolith/Insider Trading/DMAC/Form 4

Wambeke David J.

Chief Business OfficerDiaMedica Therapeutics Inc. (DMAC) · full profile →Form 4 · filed Apr 11, 2023
Net Buying
Open-Market Buys
$750K
Open-Market Sells
$0
Net Open-Market Flow
$750K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 10, 2023Buy(P)469K$1.60$750K469K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 10, 2023Grant(A)140K—$0140K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001235802-23-000040) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML